NCI clinical trials will cover areas neglected by industry

NCI will focus its clinical research on topics that are neglected by industry, including low-prevalence cancers and the de-escalation of therapeutic intensity, NCI Director Norman (Ned) Sharpless said in remarks Friday and in a Viewpoint published Thursday

Read the full 370 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE